Journal of Clinical Endocrinology & Metabolism, Vol 76, 216-222, Copyright © 1993 by Endocrine Society

ARTICLES

Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation

D Zimmerman, WF Young Jr, MJ Ebersold, BW Scheithauer, K Kovacs, E Horvath, MD Whitaker, NL Eberhardt, TR Downs and LA Frohman
Department of Pediatrics, Mayo Clinic, Rochester, Minnesota 55905.

The cause of gigantism in most patients is a GH-secreting pituitary tumor. In this report, a case of congenital gigantism due to probable central hypersection of GH-releasing hormone (GHRH) is described. Normal at birth (4.4 kg; 53 cm), our 7-yr-old male patient grew progressively thereafter to attain a height of 182 cm and a weight of 99.4 kg at the time of our evaluation. The markedly increased baseline plasma levels of GH (730 micrograms/L) did not suppress during a standard 3-h oral glucose tolerance test, but did increase 54% after iv infusion of GHRH. Baseline plasma levels of insulin-like growth factor- I, PRL, and immunoreactive GHRH were also markedly increased. Computed imaging of the head showed a large, partially cystic sellar and suprasellar mass. Extensive imaging studies did not localize a potential source of GHRH. Preoperative treatment with octreotide and bromocriptine for 4 months resulted in a 25% reduction of suprasellar tissue mass. The pituitary tissue removed at transsphenoidal and transfrontal operations showed massive somatotroph, lactotroph, and mammosomatotroph hyperplasia. Areas of GH- and PRL-secreting cell adenomatous transformation were also evident. No histological or immunohistochemical evidence of a pituitary source of GHRH was found. The peripheral plasma immunoreactive GHRH concentration remained unaffected by pharmacological and surgical interventions. We suspect that a congenital hypothalamic regulatory defect may be responsible for the GHRH excess in this case.

This article has been cited by other articles:

				M Rix, P Laurberg, A S Hoejberg, and B Brock-Jacobsen Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl Eur. J. Endocrinol., August 1, 2005; 153(2): 195 - 201. [Abstract] [Full Text] [PDF]

				H. G. Maheshwari, T. R. Prezant, V. Herman-Bonert, H. Shahinian, K. Kovacs, and S. Melmed Long-Acting Peptidomimergic Control of Gigantism Caused by Pituitary Acidophilic Stem Cell Adenoma J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3409 - 3416. [Abstract] [Full Text]

				N. Sanno, A. Teramoto, R. Y. Osamura, S. Genka, H. Katakami, L. Jin, R. V. Lloyd, and K. Kovacs A Growth Hormone-Releasing Hormone-Producing Pancreatic Islet Cell Tumor Metastasized to the Pituitary Is Associated with Pituitary Somatotroph Hyperplasia and Acromegaly J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2731 - 2737. [Abstract] [Full Text] [PDF]

				J. F. Sotos Overgrowth Clinical Pediatrics, November 1, 1996; 35(11): 577 - 590. [PDF]